Rapid Reduction of HbA1c and Weight in Elderly Patient with Type 2 Diabetes (T2D) And Depression by Oral Semaglutide (Rybelsus)

Abstract

Background: Oral semaglutide (Rybelsus) has been in focus for type 2 diabetes (T2D). Case Presentation: The patient is a 73-year-old male with T2D treated with metformin, Ipragliflozin, and rosuvastatin. He was diagnosed with depression by the Geriatric depression scale (GDS) with a stable condition by mirtazapine. His diabetic control was exacerbated to HbA1c 8.8% and weight 63.5kg in Feb 2022. Results: He started to take Rybelsus, and then clinical improvement was found as HbA1c 6.9% and weight 57.5kg for 4 months. Discussion: Remarkable effect of HbA1c and weight may be from longer fasting time after post-med, and regular lifestyle from the stable psychosomatic situation.

Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

“…For decades, oral hypoglycemic agents (OHAs) have been surprisingly developed. Recent OHAs include sodium-glucose cotransporter 2 inhibitor (SGLT2i) and oral administration of glucagon-like-peptide 1 receptor agonist (GLP1-RA) [4]. Furthermore, the latest novel OHA is imeglimin (Twemeeg) that shows dual efficacy of increasing insulin secretion and decreasing insulin resistance [5,6].…”

Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

“…They have presented significant effects in maintaining glucose variability, including dipeptidyl peptidase-4 inhibitor (DPP-4i), glucagon-like-peptide 1 receptor agonist (GLP1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and others [6]. The latest topic in OHA would be imeglimin (Twymeeg), which has a characteristic efficacy of a dual mechanism [5,7].…”